First Vyluma product tackles pediatric myopia


Dive deep into Vyluma’s investigational atropine therapy. Navneet Puri, PhD, the company’s founder, chairman, and CEO, explains details of the clinical trials.

Related Videos
Brianna Rhue, OD, FAAO, FSLS
Justin Kwan, OD, FAAO
Kevin Chan, OD, MS, FAAO, presents "Top 5 myopia management myths and how to overcome them" at AOA 2023 in Washington DC
© 2023 MJH Life Sciences

All rights reserved.